The therapeutic monoclonal antibody market, the industry's fastest growing molecule type sector, is expected to maintain its impressive growth out to 2016. Within this market an emerging class of therapies will increase in importance over the coming six years, which will be introduced in this report. Additionally, the key companies and pipeline candidates for each technology will be profiled.
Call Girls Coimbatore Just Call 9907093804 Top Class Call Girl Service Available
Emerging technologies new antibody based technologies
1. Emerging Technologies: New Antibody-Based Technologies
Published:September 2011
No.Of Pages:62
Price:US $ 5700
Introduction
The therapeutic monoclonal antibody market, the industry's fastest growing molecule type
sector, is expected to maintain its impressive growth out to 2016. Within this market an
emerging class of therapies will increase in importance over the coming six years, which will
be introduced in this report. Additionally, the key companies and pipeline candidates for
each technology will be profiled.
Features and benefits
* Gain insight into the sector's outlook across the next 6 years
* Analyze each technology's pipeline candidates and the respective key companies involved
Highlights
Six new antibody-based technologies will be introduced with the key players for each of the
technologies profiled. A full pipeline assessment of technology (from preclinical to late
stage) will be provided. Finally, the market forecast for this emerging sector will be
benchmarked with the entire prescription pharmaceutical market.
Table Of Contents
ABOUT THIS REPORT
PharmaVitae Explorer database
Chapter structure
Biologics market dynamics
The technologies and key players
Product profiles
Data sourcing
Analyst consensus
EXECUTIVE SUMMARY
Key findings
Introducing the new antibody-based technologies
The development pipeline landscape of new antibody-based technologies
The leading companies driving new antibody-based technology development
New antibody-based technology commercial return over 2010–16
The MAb market will continue to be the fastest-growing sector across the entire
pharmaceutical industry
2. BIOLOGICS MARKET DYNAMICS
Key findings
Introduction to the PharmaVitae company universe
The prescription pharmaceutical market performance, 2010–16
Prescription pharmaceutical market performance, 2010–16
Biologics driven growth, 2010–16
Introduction to molecule type analysis
Prescription pharmaceutical market, by molecule type, 2004–16
The MAb market will continue to be the fastest growing sector across the entire
pharmaceutical industry
New antibody-based technologies
Antibody-drug conjugates will be the key driver in an emerging class
THE TECHNOLOGIES AND KEY PLAYERS
Key findings
Overview of the emerging antibody-based technologies
Antibody-drug conjugates
Mylotarg's withdrawal was a blow to the ADC market
Oncology is the most active area of ADC development
ADC key players
Seattle Genetics
ImmunoGen
Bispecific and trifunctional antibodies
(Untitled sub-section)
Trifunctional antibodies
Domain antibodies and nanobodies
Domain antibodies: GSK – through Domantis – leads the field
Ablynx’s nanobodies
Fc-engineered antibodies
PRODUCT PROFILES
Removab
Adcetris
Trastuzumab emtansine
Inotuzumab ozogamicin
GA101/RG-7159
APPENDIX
References
Datamonitor research
Exchange rates
3. LIST OF TABLES
Table: Number of pipeline candidates, by company, 2011
Table: New antibody-based technology market launches, 2010–16
Table: MAb market sales, by technology type ($m), 2010–16
Table: PharmaVitae company coverage, by peer set
Table: Molecule type definitions
Table: General characteristics of small molecule drugs versus biologics
Table: Prescription pharmaceutical sales, by molecule type ($m), 2010–16
Table: MAb market sales, by technology type ($m), 2010–16
Table: Emerging technologies overview, 2011
Table: Technology count by development stage, 2011
Table: Antibody drug conjugate candidates
Table: Bispecific and trifunctional antibody candidates
Table: Domain antibody and nanobody candidates
Table: Antibody-drug conjugates candidates
Table: Removab: overview
Table: Adcetris: overview
Table: trastuzumab emtansine: overview
Table: inotuzumab ozogamicin: overview
Table: GA101/RG-7159: overview
Table: Exchange rates, 2011
LIST OF FIGURES
Figure: The PharmaVitae Explorer
Figure: New antibody-based technologies, preclinical-approved, 2011
Figure: Total sales of the MAb market ($m and %), 2004–16
Figure: Proportion of sales of the MAb market from new antibody-based technologies (%),
2004–16
Figure: The total pharmaceutical market outlook, sales ($m) and year-on-year growth rate
(%), 2004–16
Figure: Total sales of the prescription pharmaceutical market ($m), 2004–16
Figure: Total sales growth of the prescription pharmaceutical market, by molecule type
($bn), 2004–16
Figure: Total sales of the MAb market ($m and %), 2004–16
Figure: MAb market sales, by technology type ($m), 2004-16
Figure: Technology count by development stage, 2011
About Us:
ReportsnReports is an online library of over 100,000+ market research reports and in-depth
market research studies & analysis of over 5000 micro markets. We provide 24/7 online and
offline support to our customers. Get in touch with us for your needs of market research
reports.
Follow us on Twitter: http://twitter.com/marketsreports
Our Facebook Page: http://www.facebook.com/pages/ReportsnReports/191441427571689
